A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia

Dr, Weinberger; Jones, Douglas W.; Rc, Reba; Mann, Ulrike; Coppola, Richard; Gibson, Ron; Gorey, Julia G.; Braun, Andrew; Chase, T. N.

doi:10.1176/jnp.4.3.239

Cited by 42 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Weinberger et al found that when 123 I-4-IQNB was used in SPECT, the brain region with strong binding to the muscarinic acetylcholine receptor was not correlated with the glucose metabolism intensity measured by FDG-PET, and the defect range was larger in AD patients. In patients with AD, the signal of the tracer showed differences in the expression of receptors in different brain regions (55).…”

Section: Targeted Neurotransmitter Tracers/probesmentioning

confidence: 99%

Identification of Alzheimer’s Disease by Molecular Imaging: Progress and Prospects

Xing,

Lv,

Guo

et al. 2024

Preprint

View full text Add to dashboard Cite

Alzheimer's disease (AD), which is characterized by the development of β-amyloid plaques and neurofibrillary tangles in the brain parenchyma, can result in synaptic and neuronal loss. Clinical signs, including deteriorating memory deficiency, may lead to catastrophic effects for the elderly. Research on brain imaging and its application in the study of AD has advanced extraordinarily over the past 30 years. However, widely used imaging methods are only capable of identifying structural or metabolic alterations at the anatomical level in the brain and can only be utilized for drawing inferential distinctions. As a disease with a complex pathophysiological mechanism, AD has many different molecular pathological features and molecular biomarkers. Therefore, molecular imaging for AD pathology indicators provides a practical method for the early diagnosis and impartial assessment of AD. The present review discusses the pathogenesis of AD, as well as the detection methods and principles of molecular imaging, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) techniques. Meanwhile, various tracers and probes applied in molecular imaging that detect Aβ deposits, tau protein accumulation, and neurotransmitters are also reviewed. Molecular pathological tracers provide the possibility to accurately quantify brain changes through molecular imaging.

show abstract

Section: Targeted Neurotransmitter Tracers/probesmentioning

confidence: 99%

Identification of Alzheimer’s Disease by Molecular Imaging: Progress and Prospects

Xing,

Lv,

Guo

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Z-(-,-)-[76Br]BrQNP: A high affinity PET radiotracer for central and cardiac muscarinic receptors

Strijckmans¹,

Luo

Coulon³

et al. 1996

J Label Compd Radiopharm

View full text Add to dashboard Cite

Summary Racemic E-I-azabicyclo[2.2.2]oct-3-yl a-( 1-bromo-1-l-propen-3-yl)-u-liydroxy-a-pheiiylacetate (BrQNP) was prepared and evaluated in vivo as a potential candidate for imaging muscarinic acetylcholinergic receptors by Positron Emission Tomography. Initial in vivo blocking studies utilizing Z-(-,-)-['251]IQNP as a radiolabelled inuscariuicprobe demonstrated that a preinjection of cold E-BrQNP effectively blocks the uptake of the radiolabelled probe in the brain and heart, by 71% and 86% respectively. Z-(-,-)-[76Br]BrQNP was prepared by electrophilic substitution iYom a tributylstamyl precursor. Peracetic acid and chloramine T were evaluated as oxidizing agents. After purification by SPE and RP-HPLC, radiolabelliig yields of 85% iiiid 95% were obtained with peracetic acid and chloramine T, respectively. The final radiochemical yield was 70% for both oxidizing agents.Rat biodistribution studies of Z-(-,-)-[76Br]BrQNP showed high uptake in organs with high concentrations of muscarinic receptors (heart and brain).

show abstract

Preparation and characterization of (R,S)-[76Br]BrQNB: An analogue of QNB for PET

Strijckmans¹,

Lee

Loc’h³

et al. 1997

J Label Compd Radiopharm

View full text Add to dashboard Cite

(R,S)‐[76Br]BrQNB was prepared for imaging mAChR by PET. (R,S)QNB was labelled with bromine‐76 by electrophilic substitution of the tributylstannyl precursor using peracetic acid as oxidizing agent. The exchange between bromine‐76 and the leaving group occurred in 20 min at room temperature. A chemically and radiochemically pure product was obtained with a final radiolabelling yield of 30%. Preliminary evaluation of pharmacological properties was performed in rats. In brain, biodistribution and autoradiography studies showed that the preferential localization of (R,S)‐[76Br]BrQNB was m‐AChR rich structures. 6 h p.i. the radioactivity uptake in the posterior cortex was 1% ID/g and the striatum to cerebellum radioactivity ratio was 13.5. Metabolite study revealed that the radiotracer remains unchanged in brain for at least 3 h. © 1997 John Wiley & Sons, Ltd.

show abstract

A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia

Cited by 42 publications

References 31 publications

Identification of Alzheimer’s Disease by Molecular Imaging: Progress and Prospects

Identification of Alzheimer’s Disease by Molecular Imaging: Progress and Prospects

Z-(-,-)-[76Br]BrQNP: A high affinity PET radiotracer for central and cardiac muscarinic receptors

Preparation and characterization of (R,S)-[76Br]BrQNB: An analogue of QNB for PET

Contact Info

Product

Resources

About